At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss
The glucagon peptide family [glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon] Figure 2: Simplified schematic overview of the glucagon superfamily of peptides [28] The glucagon peptide family members [GLP-1, GIP and glucagon] have similar peptide sequences, permitting the development of single-sequence multi-receptor agonists [4]
For both pills tested, researchers saw side effects similar to those associated with other GLP-1 drugs: some nausea, vomiting, diarrhea and constipation
Volume-based, fee-for-service primary health care systems seem to have very little clinical approach other than prescribing GLP-1s at a patients request. An advanced primary care model, which focuses on quality of care over quantity of services, uses a holistic approach as a best practice
Y.WangZ.ParkJ
Someone may be thin with little subcutaneous fat but can still have significant visceral fat, while someone with significant subcutaneous fat may not have as much visceral fat